Recent submissions
Now showing items 1741-1760 of 4704
-
Next-generation sequencing for the management of sarcomas with no known driver mutations.
(LIPPINCOTT WILLIAMS & WILKINS, 2021-07-01)PURPOSE OF REVIEW: Next-generation sequencing (NGS) has enabled fast, high-throughput nucleotide sequencing and has begun to be implemented into clinical practice for genomic-guided precision medicine in various cancer ... -
Whole-body MRI: a practical guide for imaging patients with malignant bone disease.
(W B SAUNDERS CO LTD, 2021-10-01)Whole-body magnetic resonance imaging (MRI) is now a crucial tool for the assessment of the extent of systemic malignant bone disease and response to treatment, and forms part of national and international recommendations ... -
Deciphering genetic susceptibility to multiple myeloma
(Institute of Cancer Research (University Of London), 2020-09-30)Multiple myeloma (MM) is a malignancy characterised by the clonal expansion of plasma cells primarily from the bone marrow. The two- to four-fold increased risk observed in relatives of MM patients provides support for ... -
Searching for treatments for non-G12C-KRAS mutant cancers.
(SPRINGERNATURE, 2021-08-31)KRAS mutations drive a wide variety of cancers. Drugs targeting the protein product of KRASG12C mutations are currently being evaluated show preliminary efficacy in clinical trials. A clinical trial of VS-6766, a dual ... -
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.
(NATURE PORTFOLIO, 2021-04-16)Five to ten percent of ER+ metastatic breast cancer (MBC) tumors harbor somatic PTEN mutations. Loss of function of this tumor-suppressor gene defines a highly aggressive, treatment-refractory disease for which new therapies ... -
Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche.
(BMJ PUBLISHING GROUP, 2021-01-01)BACKGROUND: Multiple myeloma (MM) remains an incurable disease and oncolytic viruses offer a well-tolerated addition to the therapeutic arsenal. Oncolytic reovirus has progressed to phase I clinical trials and its direct ... -
Circulating microRNA-652-3p as a biomarker of regorafenib resistance in metastatic colorectal cancer patients
(Institute of Cancer Research (University Of London), 2020-09-30)MicroRNAs (miRNAs) are small non-coding RNAs involved in cell homeostasis. MiRNAs dysregulation has been linked with activation of oncogenic pathways, cancer progression and clinical outcome in metastatic colorectal cancer ... -
Deciphering the genomic landscape and evolution in multiple myeloma
(Institute of Cancer Research (University Of London), 2020-09-30)Multiple myeloma (MM) is the second commonest haematological cancer in Western countries, with most patients dying from progressive disease after relapse. Currently, the molecular mechanisms responsible for the initiation ... -
Investigating the molecular mechanisms of fraction size sensitivity in irradiated cells
(Institute of Cancer Research (University Of London), 2020-09-30)Fractionated radiotherapy is used clinically when it spares healthy tissue relative to the cancer; the healthy tissue is described as more fraction size sensitive. However, a molecular understanding of the mechanisms that ... -
Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma.
(ELSEVIER SCI LTD, 2021-05-25) -
Systems level profiling of chemotherapy-induced stress resolution in cancer cells reveals druggable trade-offs.
(NATL ACAD SCIENCES, 2021-04-27)Cancer cells can survive chemotherapy-induced stress, but how they recover from it is not known. Using a temporal multiomics approach, we delineate the global mechanisms of proteotoxic stress resolution in multiple myeloma ... -
The use of germline genetic profiles to guide prostate cancer targeted screening and cancer care
(Institute of Cancer Research (University Of London), 2020-09-30)The genetic heritability of prostate cancer is contributed to by rarely occurring but high penetrant genetic variants, and moderate to commonly occurring variants conferring lower risks. Genome wide association studies and ... -
Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer.
(MDPI, 2021-05-10)Lung cancer is the most common cause of cancer-related deaths globally. Genetic alterations, such as amplifications, mutations and translocations in the fibroblast growth factor receptor (FGFR) family have been found in ... -
Taste dysfunction following radiotherapy to the head and neck: A systematic review.
(ELSEVIER IRELAND LTD, 2021-04-01)BACKGROUND: An intact sense of taste provides pleasure, supports sustenance and alerts the body to toxins. Head and neck cancer (HNC) patients who receive radiotherapy (RT) are high-risk for developing radiation-induced ... -
Cancer progression: A journey through the past (with the same stops)?
(WILEY, 2021-05-04) -
Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data.
(2020-09-28)BACKGROUND:It is unclear whether adjuvant or early salvage radiotherapy following radical prostatectomy is more appropriate for men who present with localised or locally advanced prostate cancer. We aimed to prospectively ... -
Monitoring advances including consent: learning from COVID-19 trials and other trials running in UKCRC registered clinical trials units during the pandemic.
(BMC, 2021-04-14)The COVID-19 pandemic has affected how clinical trials are managed, both within existing portfolios and for the rapidly developed COVID-19 trials. Sponsors or delegated organisations responsible for monitoring trials have ... -
Single dose prostate radiotherapy - a step too far?
(2021-04-21) -
ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology.
(2021-03-26)Online magnetic resonance-guided radiotherapy (oMRgRT) represents one of the most innovative applications of current image-guided radiation therapy (IGRT). The revolutionary concept of oMRgRT systems is the ability to ... -
Fracture Risk in Men with Metastatic Prostate Cancer Treated With Radium-223.
(CIG MEDIA GROUP, LP, 2021-10-01)BACKGROUND: Radium-223 is a bone-seeking, alpha-emitting radionuclide used in metastatic castration-resistant prostate cancer (mCRPC). Radium-223 increases the risk of fracture when used in combination with abiraterone and ...